Zacks Research Has Negative Outlook of CRDF FY2027 Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Stock analysts at Zacks Research lowered their FY2027 EPS estimates for shares of Cardiff Oncology in a report issued on Monday, March 2nd. Zacks Research analyst J. Vandermosten now expects that the company will post earnings of ($0.75) per share for the year, down from their prior estimate of ($0.74). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share.

Cardiff Oncology (NASDAQ:CRDF) last released its earnings results on Tuesday, February 24th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07. The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.13 million. Cardiff Oncology had a negative net margin of 7,733.22% and a negative return on equity of 82.01%.

A number of other equities research analysts have also weighed in on CRDF. Noble Financial started coverage on Cardiff Oncology in a research note on Monday, January 5th. They issued an “outperform” rating and a $12.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Piper Sandler dropped their price objective on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Cardiff Oncology in a report on Wednesday, January 28th. Finally, Wall Street Zen raised shares of Cardiff Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Cardiff Oncology has a consensus rating of “Moderate Buy” and an average target price of $10.10.

Cardiff Oncology Stock Down 5.6%

NASDAQ CRDF opened at $1.87 on Wednesday. The company has a 50-day simple moving average of $2.24 and a two-hundred day simple moving average of $2.24. Cardiff Oncology has a 12-month low of $1.48 and a 12-month high of $4.56. The firm has a market cap of $127.83 million, a price-to-earnings ratio of -2.71 and a beta of 1.32.

Institutional Trading of Cardiff Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRDF. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Cardiff Oncology by 50.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,319 shares of the company’s stock worth $108,000 after purchasing an additional 11,497 shares in the last quarter. Rhumbline Advisers increased its position in shares of Cardiff Oncology by 18.8% during the first quarter. Rhumbline Advisers now owns 63,142 shares of the company’s stock valued at $198,000 after buying an additional 9,970 shares during the period. Los Angeles Capital Management LLC bought a new position in Cardiff Oncology in the second quarter worth about $78,000. Geode Capital Management LLC raised its stake in Cardiff Oncology by 7.5% in the second quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock worth $4,723,000 after buying an additional 104,409 shares in the last quarter. Finally, AlphaCore Capital LLC purchased a new stake in Cardiff Oncology in the second quarter worth about $320,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.